Back to search results
NCT07490301

A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal Adenocarcinoma

Recruiting
PHASE2Ages 18+InterventionalTreatment
AbbVie
~900 participants
Updated 2026-09-01 on ClinicalTrials.gov
What's tested:Telisotuzumab adizutecanFluorouracilFolinic acid/ LeucovorinaOxaliplatinIrinotecan

At a glance

Recruiting sites
19 of 19 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Phase 2 and Phase 3: Overall Response (OR) Assessed by Blinded Independent Central Review (BICR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
Measured over through study completion, approximately 6 years
+1 more outcome measured

Conditions

Metastatic Pancreatic Ductal Adenocarcinoma
PDAC

Explore related trials

Pancreatic Ductal Adenocarcinoma

NCT07490301

Where you'd take part

This study runs at 19 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Austin Hospital /ID# 280283

    Melbourne, Victoria, Australiano site contact published

    Recruiting

  • Cancer And Hematology Centers Of Western Michigan - Grand Rapids /ID# 279853

    Grand Rapids, Michiganno site contact published

    Recruiting

  • China Medical University Hospital /ID# 279725

    Taichung, Taiwanno site contact published

    Recruiting

  • City Of Hope - Chicago /ID# 279814

    Zion, Illinoisno site contact published

    Recruiting

  • Hadassah Medical Center-Hebrew University /ID# 279411

    Jerusalem, Israelno site contact published

    Recruiting

  • Kaohsiung Medical University Chung-Ho Memorial Hospital /ID# 279735

    Kaohsiung City, Taiwanno site contact published

    Recruiting

  • Oxford University Hospital NHS Trust /ID# 279764

    Oxford, Oxfordshire, United Kingdomno site contact published

    Recruiting

  • Rambam Health Care Campus- Haifa /ID# 279409

    Haifa, Israelno site contact published

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • ABBVIE INC. · STUDY_DIRECTOR · AbbVie

Who to contact

ABBVIE CALL CENTER
[email protected]
844-663-3742
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Have unresectable, metastatic histologically- or cytologically-confirmed adenocarcinoma of the pancreas
Have an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1
Must consent to provide archived or recently obtained tumor tissue during Screening
Have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.

Exclusion

Have prior systemic therapy, surgery, or radiation (except palliative radiation) in the unresectable, locally advanced or metastatic setting
Prior c-MET targeting therapy
History of interstitial lung disease (ILD) or pneumonitis that required treatment with systemic steroids, or any evidence of active ILD/pneumonitis on screening chest computed tomography (CT) scan, including a history of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis.
Prior bone marrow transplant, solid organ transplant, or previous clinical diagnosis of tuberculosis.

What this trial measures

  • Phase 2 and Phase 3: Overall Response (OR) Assessed by Blinded Independent Central Review (BICR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1through study completion, approximately 6 years

    OR is defined as participants achieving a best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR) assessed by BICR per RECIST v1.1.

  • Phase 3: Overall Survival (OS)through study completion, approximately 6 years

    OS is defined as the time from date of randomization to the death from any cause.